Skip to main content

Table 2 Associations of clinical characteristics with QTc length in combined SLE/RA cohort

From: Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients

Clinical covariates Univariable model QTc (continuous) Multivariable model QTc (continuous)a
Β p Β p
Age 0.38 < 0.005 0.21 0.033
Sex 0.31 0.92 ---------- ----------
Race (white vs non-white) 6.2 < 0.05 − 0.29 0.92
Disease duration (square root) − 0.1 0.86 ---------- ----------
Current HCQ use 7.8 < 0.005 0.22 0.95
Current prednisone use − 9.8 < 0.005 8.27 0.018
Current biologic use 0.45 0.87 ---------- ----------
Hypertension 3.6 0.11 3.01 0.29
Current smoking 10.6 < 0.05 10.2 0.033
Diabetes 8.9 < 0.05 0.69 0.88
Current statin use 2.7 0.38 ---------- ----------
Current aspirin use − 7.1 < 0.05 − 3.9 0.22
Any QTc meds − 1.4 0.56 ---------- ----------
Antidepressants 7.1 < 0.05 ---------- ----------
Antipsychotics − 1.6 0.80 ---------- ----------
Antiarrhythmics 5.4 0.49 ---------- ----------
Muscle relaxants 9.6 0.12 ---------- ----------
Antimicrobials − 0.2 0.96 − 2.4 0.46
Antiemetics 1.8 0.63 ---------- ----------
Anticonvulsants 7.9 0.21 ---------- ----------
Tacrolimus − 0.5 0.92 ---------- ----------
Ejection fraction % 0.05 0.77 ---------- ----------
Ejection fraction ≥ 55% − 3.2 0.47 ---------- ----------
Prob > F ---------- 0.0001
  1. Abbreviations: HCQ hydroxychloroquine, QtC QT corrected interval
  2. aFinal imputed data